Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-DFO-MAB4219
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
89Zr-DFO-MAB4219 is a zirconium-89 labeled, deferoxamine (DFO)-conjugated monoclonal antibody targeting Claudin-4 (CLDN4), a tight junction protein frequently overexpressed in colorectal cancer and other epithelial malignancies. Developed preclinically by researchers at the University of Texas MD Anderson Cancer Center, this radiotheranostic probe is designed for positron emission tomography (PET) imaging of metastatic colorectal cancer (mCRC). By leveraging the disrupted junctional architecture and aberrant surface exposure of CLDN4 in malignant tissues, 89Zr-DFO-MAB4219 enables selective tumor-specific visualization and serves as a diagnostic companion to therapeutic radiopharmaceuticals targeting the same pathway.
- Other names
- 89Zr-DFO-anti-CLDN4 mAb89Zr-DFO-anti-claudin-4 mAb[89Zr]Zr-DFO-MAB4219
02
Targets
CLDN4 (Claudin-4)
Beyond the preview
Go deeper on 89Zr-DFO-MAB4219.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-DFO-MAB4219.